These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

553 related items for PubMed ID: 35134633

  • 1. Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: A systematic review.
    McPherson M, Economidou S, Liampas A, Zis P, Parperis K.
    Semin Arthritis Rheum; 2022 Apr; 53():151959. PubMed ID: 35134633
    [Abstract] [Full Text] [Related]

  • 2. Management of Myositis-Associated Interstitial Lung Disease.
    Fujisawa T.
    Medicina (Kaunas); 2021 Apr 03; 57(4):. PubMed ID: 33916864
    [Abstract] [Full Text] [Related]

  • 3. Comparison of characteristics and anti-MDA5 antibody distribution and effect between clinically amyopathic dermatomyositis and classic dermatomyositis: a retrospective case-control study.
    Ji Q, Pan W, Zhang D, Hou Y, Wang Z.
    Front Immunol; 2023 Apr 03; 14():1237209. PubMed ID: 38098481
    [Abstract] [Full Text] [Related]

  • 4. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment.
    Koichi Y, Aya Y, Megumi U, Shunichi K, Masafumi S, Hiroaki M, Masahiko K, Shinsuke K, Manabu U, Kenichiro H, Fumiaki A, Nozomi A, Toshitaka M, Masayoshi Y, Chikako K, Yoshinao M, Tatsuo S, Masahiko K.
    Mod Rheumatol; 2017 May 03; 27(3):536-540. PubMed ID: 25698373
    [Abstract] [Full Text] [Related]

  • 5. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
    Yamaguchi K, Yamaguchi A, Kashiwagi C, Sawada Y, Taguchi K, Umetsu K, Oshima K, Uchida M, Suzuki M, Kono S, Takemura M, Masubuchi H, Kitahara S, Hara K, Maeno T, Motegi SI, Muro Y, Sakairi T, Hisada T, Kurabayashi M.
    Respir Med; 2018 Jul 03; 140():1-5. PubMed ID: 29957268
    [Abstract] [Full Text] [Related]

  • 6. Anti-MDA5 Antibody-positive Clinically Amyopathic Dermatomyositis with Rapidly Progressing Interstitial Lung Disease Successfully Treated by Initiation of Combined Immunosuppressive Therapy Plus Plasma Exchange and Subsequently Switching Tacrolimus to Tofacitinib.
    Yamazoe M, Takeda K, Nagano Y, Nagano K, Kato K, Inoue T, Horiuchi K, Kamada K.
    Intern Med; 2024 Sep 15; 63(18):2571-2578. PubMed ID: 38346740
    [Abstract] [Full Text] [Related]

  • 7. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease.
    Xu A, Ye Y, Fu Q, Lian X, Chen S, Guo Q, Lu LJ, Dai M, Lv X, Bao C.
    Rheumatology (Oxford); 2021 Jul 01; 60(7):3343-3351. PubMed ID: 33331866
    [Abstract] [Full Text] [Related]

  • 8. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
    Matsushita T, Mizumaki K, Kano M, Yagi N, Tennichi M, Takeuchi A, Okamoto Y, Hamaguchi Y, Murakami A, Hasegawa M, Kuwana M, Fujimoto M, Takehara K.
    Br J Dermatol; 2017 Feb 01; 176(2):395-402. PubMed ID: 27452897
    [Abstract] [Full Text] [Related]

  • 9. Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?
    Ikeda S, Arita M, Morita M, Ikeo S, Ito A, Tokioka F, Noyama M, Misaki K, Notohara K, Ishida T.
    BMC Pulm Med; 2015 Dec 09; 15():159. PubMed ID: 26651481
    [Abstract] [Full Text] [Related]

  • 10. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
    Sakamoto N, Ishimoto H, Nakashima S, Yura H, Miyamura T, Okuno D, Hara A, Kitazaki T, Kakugawa T, Ishimatsu Y, Satoh M, Mukae H.
    Intern Med; 2019 Mar 15; 58(6):837-841. PubMed ID: 30449789
    [Abstract] [Full Text] [Related]

  • 11. Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review.
    Gil B, Merav L, Pnina L, Chagai G.
    Clin Rheumatol; 2016 Aug 15; 35(8):2125-2130. PubMed ID: 25846833
    [Abstract] [Full Text] [Related]

  • 12. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
    Fujisawa T, Hozumi H, Yasui H, Suzuki Y, Karayama M, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Suda T.
    J Rheumatol; 2019 Aug 15; 46(8):935-942. PubMed ID: 31092718
    [Abstract] [Full Text] [Related]

  • 13. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.
    Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R.
    Arthritis Care Res (Hoboken); 2016 May 15; 68(5):689-94. PubMed ID: 26414240
    [Abstract] [Full Text] [Related]

  • 14. Lung histopathological pattern in a survivor with rapidly progressive interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis.
    Suzuki A, Kondoh Y, Taniguchi H, Tabata K, Kimura T, Kataoka K, Ono K, Hashisako M, Fukuoka J.
    Respir Med Case Rep; 2016 May 15; 19():5-8. PubMed ID: 27354955
    [Abstract] [Full Text] [Related]

  • 15. Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis.
    Xu Y, Yang CS, Li YJ, Liu XD, Wang JN, Zhao Q, Xiao WG, Yang PT.
    Clin Rheumatol; 2016 Jan 15; 35(1):113-6. PubMed ID: 26660480
    [Abstract] [Full Text] [Related]

  • 16. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.
    Horiike Y, Suzuki Y, Fujisawa T, Yasui H, Karayama M, Hozumi H, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Ogawa N, Suda T.
    Rheumatology (Oxford); 2019 Dec 01; 58(12):2143-2152. PubMed ID: 31143953
    [Abstract] [Full Text] [Related]

  • 17. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.
    Huang K, Vinik O, Shojania K, Yeung J, Shupak R, Nimmo M, Avina-Zubieta JA.
    Rheumatol Int; 2019 Nov 01; 39(11):1971-1981. PubMed ID: 31375890
    [Abstract] [Full Text] [Related]

  • 18. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis.
    So H, Wong VTL, Lao VWN, Pang HT, Yip RML.
    Clin Rheumatol; 2018 Jul 01; 37(7):1983-1989. PubMed ID: 29713969
    [Abstract] [Full Text] [Related]

  • 19. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
    Motegi SI, Sekiguchi A, Toki S, Kishi C, Endo Y, Yasuda M, Ikeuchi H, Sakairi T, Hara K, Yamaguchi K, Maeno T, Hiromura K, Ishikawa O.
    Eur J Dermatol; 2019 Oct 01; 29(5):511-517. PubMed ID: 31617496
    [Abstract] [Full Text] [Related]

  • 20. Successful treatment with tofacitinib for relapse of rapidly progressive interstitial lung disease in anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis.
    Hama S, Akiyama M, Higashida-Konishi M, Oshige T, Takei H, Izumi K, Oshima H, Okano Y.
    Mod Rheumatol Case Rep; 2023 Jan 03; 7(1):92-95. PubMed ID: 35680682
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.